![CIRRUS 6000]({"xsmall":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/ga_cropped_1.jpg/_jcr_content/renditions/original.image_file.100.56.file/ga_cropped_1.jpg","small":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/ga_cropped_1.jpg/_jcr_content/renditions/original.image_file.360.203.file/ga_cropped_1.jpg","medium":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/ga_cropped_1.jpg/_jcr_content/renditions/original.image_file.768.432.file/ga_cropped_1.jpg","large":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/ga_cropped_1.jpg/_jcr_content/renditions/original.image_file.1024.576.file/ga_cropped_1.jpg","xlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/ga_cropped_1.jpg/_jcr_content/renditions/original.image_file.1280.720.file/ga_cropped_1.jpg","xxlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/ga_cropped_1.jpg/_jcr_content/renditions/original.image_file.1440.810.file/ga_cropped_1.jpg","max":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/ga_cropped_1.jpg/_jcr_content/renditions/original./ga_cropped_1.jpg"} "CIRRUS 6000")
CIRRUS OCT
Kit de herramientas AMD y atrofia geográfica
Ofrezca a sus pacientes todas las oportunidades para acceder a la emocionante nueva era del tratamiento y cuidado de la AMD con Advanced RPE Analysis y ZEISS AngioPlex, el kit de herramientas para AMD y atrofia geográfica de ZEISS CIRRUS.
La degeneración macular asociada a la edad (AMD) es la principal causa de pérdida grave e irreversible de visión en personas mayores de 60 años, y está aumentando a un ritmo alarmante en todo el mundo. Sus pacientes pueden estar en riesgo. Se calcula que 196 millones de personas padecían AMD en 2020, y que esa cifra aumentará a 288 millones en 2040. Sin embargo, el 25 % de los casos de AMD en el ámbito de la atención ocular primaria quedan sin diagnosticar.1,2 Esto supone un aumento de más del 46 %: 92 millones de personas más que pueden encontrarse en riesgo de perder la visión, y ni siquiera saben que está ocurriendo. Nosotros podemos ayudarlas. Aprenda a utilizar conjuntamente Advanced RPE Analysis y AngioPlex® como un kit de herramientas para AMD y atrofia geográfica para el diagnóstico y la gestión de sus pacientes con AMD.
![]({"xsmall":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/196-million.png/_jcr_content/renditions/original.image_file.100.100.80,0,560,480.file/196-million.png","small":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/196-million.png/_jcr_content/renditions/original.image_file.360.360.80,0,560,480.file/196-million.png","medium":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/196-million.png/_jcr_content/renditions/original.image_file.480.480.80,0,560,480.file/196-million.png","large":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/196-million.png/_jcr_content/renditions/original.image_file.480.480.80,0,560,480.file/196-million.png","xlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/196-million.png/_jcr_content/renditions/original.image_file.480.480.80,0,560,480.file/196-million.png","xxlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/196-million.png/_jcr_content/renditions/original.image_file.480.480.80,0,560,480.file/196-million.png","max":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/196-million.png/_jcr_content/renditions/original.image_file.480.480.80,0,560,480.file/196-million.png"})
Se calcula que 196 millones de personas padecían AMD en 2020.
![]({"xsmall":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/affect-central-vision_lrg.jpg/_jcr_content/renditions/original.image_file.100.100.23,0,428,405.file/affect-central-vision_lrg.jpg","small":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/affect-central-vision_lrg.jpg/_jcr_content/renditions/original.image_file.360.360.23,0,428,405.file/affect-central-vision_lrg.jpg","medium":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/affect-central-vision_lrg.jpg/_jcr_content/renditions/original.image_file.405.405.23,0,428,405.file/affect-central-vision_lrg.jpg","large":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/affect-central-vision_lrg.jpg/_jcr_content/renditions/original.image_file.405.405.23,0,428,405.file/affect-central-vision_lrg.jpg","xlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/affect-central-vision_lrg.jpg/_jcr_content/renditions/original.image_file.405.405.23,0,428,405.file/affect-central-vision_lrg.jpg","xxlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/affect-central-vision_lrg.jpg/_jcr_content/renditions/original.image_file.405.405.23,0,428,405.file/affect-central-vision_lrg.jpg","max":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/affect-central-vision_lrg.jpg/_jcr_content/renditions/original.image_file.405.405.23,0,428,405.file/affect-central-vision_lrg.jpg"})
La AMD afecta a la visión central y otros 92 millones de personas pueden estar en riesgo de perder la visión.
![]({"xsmall":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/60-plus.png/_jcr_content/renditions/original.image_file.100.100.80,0,560,480.file/60-plus.png","small":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/60-plus.png/_jcr_content/renditions/original.image_file.360.360.80,0,560,480.file/60-plus.png","medium":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/60-plus.png/_jcr_content/renditions/original.image_file.480.480.80,0,560,480.file/60-plus.png","large":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/60-plus.png/_jcr_content/renditions/original.image_file.480.480.80,0,560,480.file/60-plus.png","xlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/60-plus.png/_jcr_content/renditions/original.image_file.480.480.80,0,560,480.file/60-plus.png","xxlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/60-plus.png/_jcr_content/renditions/original.image_file.480.480.80,0,560,480.file/60-plus.png","max":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/60-plus.png/_jcr_content/renditions/original.image_file.480.480.80,0,560,480.file/60-plus.png"})
Las personas mayores de 60 años corren un mayor riesgo de desarrollar AMD.
![]({"xsmall":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/risk-factors_lrg.jpg/_jcr_content/renditions/original.image_file.100.100.23,0,428,405.file/risk-factors_lrg.jpg","small":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/risk-factors_lrg.jpg/_jcr_content/renditions/original.image_file.360.360.23,0,428,405.file/risk-factors_lrg.jpg","medium":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/risk-factors_lrg.jpg/_jcr_content/renditions/original.image_file.405.405.23,0,428,405.file/risk-factors_lrg.jpg","large":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/risk-factors_lrg.jpg/_jcr_content/renditions/original.image_file.405.405.23,0,428,405.file/risk-factors_lrg.jpg","xlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/risk-factors_lrg.jpg/_jcr_content/renditions/original.image_file.405.405.23,0,428,405.file/risk-factors_lrg.jpg","xxlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/risk-factors_lrg.jpg/_jcr_content/renditions/original.image_file.405.405.23,0,428,405.file/risk-factors_lrg.jpg","max":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/risk-factors_lrg.jpg/_jcr_content/renditions/original.image_file.405.405.23,0,428,405.file/risk-factors_lrg.jpg"})
El tabaco, los antecedentes familiares, una dieta poco saludable, el sedentarismo y la exposición a la luz solar son algunos de los factores de riesgo para desarrollar AMD.
La nueva era de la atrofia geográfica
El papel de la tomografía de coherencia óptica
![Advanced RPE Analysis]({"xsmall":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/article-1-advanced-rpe-analysis/figure2-rpe_analysis_selection16_9.jpg/_jcr_content/renditions/original.image_file.100.56.1,0,1032,580.file/figure2-rpe_analysis_selection16_9.jpg","small":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/article-1-advanced-rpe-analysis/figure2-rpe_analysis_selection16_9.jpg/_jcr_content/renditions/original.image_file.360.203.1,0,1032,580.file/figure2-rpe_analysis_selection16_9.jpg","medium":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/article-1-advanced-rpe-analysis/figure2-rpe_analysis_selection16_9.jpg/_jcr_content/renditions/original.image_file.768.432.1,0,1032,580.file/figure2-rpe_analysis_selection16_9.jpg","large":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/article-1-advanced-rpe-analysis/figure2-rpe_analysis_selection16_9.jpg/_jcr_content/renditions/original.image_file.1024.576.1,0,1032,580.file/figure2-rpe_analysis_selection16_9.jpg","xlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/article-1-advanced-rpe-analysis/figure2-rpe_analysis_selection16_9.jpg/_jcr_content/renditions/original.image_file.1031.580.1,0,1032,580.file/figure2-rpe_analysis_selection16_9.jpg","xxlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/article-1-advanced-rpe-analysis/figure2-rpe_analysis_selection16_9.jpg/_jcr_content/renditions/original.image_file.1031.580.1,0,1032,580.file/figure2-rpe_analysis_selection16_9.jpg","max":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/article-1-advanced-rpe-analysis/figure2-rpe_analysis_selection16_9.jpg/_jcr_content/renditions/original.image_file.1031.580.1,0,1032,580.file/figure2-rpe_analysis_selection16_9.jpg"} "Advanced RPE Analysis")
Advanced RPE Analysis
Comparación de mediciones cuantitativas y datos históricos
El Advanced RPE Analysis, disponible en ZEISS CIRRUS OCT, se creó específicamente para ayudar a los médicos a tratar la AMD no neovascular en todas sus formas.
![AngioPlex]({"xsmall":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/article_2_figure_2-octa_report.png/_jcr_content/renditions/original.image_file.100.56.0,130,1341,886.file/article_2_figure_2-octa_report.png","small":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/article_2_figure_2-octa_report.png/_jcr_content/renditions/original.image_file.360.203.0,130,1341,886.file/article_2_figure_2-octa_report.png","medium":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/article_2_figure_2-octa_report.png/_jcr_content/renditions/original.image_file.768.432.0,130,1341,886.file/article_2_figure_2-octa_report.png","large":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/article_2_figure_2-octa_report.png/_jcr_content/renditions/original.image_file.1024.576.0,130,1341,886.file/article_2_figure_2-octa_report.png","xlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/article_2_figure_2-octa_report.png/_jcr_content/renditions/original.image_file.1280.720.0,130,1341,886.file/article_2_figure_2-octa_report.png","xxlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/article_2_figure_2-octa_report.png/_jcr_content/renditions/original.image_file.1341.754.0,130,1341,886.file/article_2_figure_2-octa_report.png","max":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/article_2_figure_2-octa_report.png/_jcr_content/renditions/original.image_file.1341.754.0,130,1341,886.file/article_2_figure_2-octa_report.png"} "AngioPlex")
AngioPlex
Importancia de la detección temprana de la progresión
Los sistemas de angiografía por OCT (OCTA), como el ZEISS CIRRUS AngioPlex®, siguen ampliando los límites de la adquisición de imágenes oculares para que los médicos puedan atender mejor a estos pacientes.
![Un modelo de atención colaborativa]({"xsmall":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/article_3_table_1-amd_classification_table.png/_jcr_content/renditions/original.image_file.100.56.84,0,2157,1166.file/article_3_table_1-amd_classification_table.png","small":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/article_3_table_1-amd_classification_table.png/_jcr_content/renditions/original.image_file.360.203.84,0,2157,1166.file/article_3_table_1-amd_classification_table.png","medium":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/article_3_table_1-amd_classification_table.png/_jcr_content/renditions/original.image_file.768.432.84,0,2157,1166.file/article_3_table_1-amd_classification_table.png","large":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/article_3_table_1-amd_classification_table.png/_jcr_content/renditions/original.image_file.1024.576.84,0,2157,1166.file/article_3_table_1-amd_classification_table.png","xlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/article_3_table_1-amd_classification_table.png/_jcr_content/renditions/original.image_file.1280.720.84,0,2157,1166.file/article_3_table_1-amd_classification_table.png","xxlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/article_3_table_1-amd_classification_table.png/_jcr_content/renditions/original.image_file.1440.810.84,0,2157,1166.file/article_3_table_1-amd_classification_table.png","max":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/article_3_table_1-amd_classification_table.png/_jcr_content/renditions/original.image_file.1920.1080.84,0,2157,1166.file/article_3_table_1-amd_classification_table.png"} "Un modelo de atención colaborativa")
Un modelo de atención colaborativa
Mejorar los resultados para el paciente
La ZEISS CIRRUS OCT con sus Advanced RPE Analysis y AngioPlex® puede proporcionar la base para que los optometristas y oftalmólogos detecten y supervisen todas las formas de AMD.
Servicios disponibles
-
1
Wong, Wan Ling, et al. «Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis». The Lancet Global Health 2.2 (2014): e106-e116
-
2
Neely DC, Bray KJ, Huisingh CE, et al. Prevalence of undiagnosed age-related macular degeneration in primary eye care. JAMA Ophthalmol. 2017;135(6):570-5